- Home
- ANGX vs NTLA Comparison
ANGX vs NTLA Comparison
Compare ANGX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | NTLA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 822.9M | 986.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ANGX | NTLA |
|---|---|---|
| Price | $5.15 | $9.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 22 |
| Target Price | $14.00 | ★ $19.83 |
| AVG Volume (30 Days) | 883.3K | ★ 4.8M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $242,655,179.00 | $57,528,000.00 |
| Revenue This Year | $205.03 | $1.96 |
| Revenue Next Year | $17.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 110.21 | 33.52 |
| 52 Week Low | $3.77 | $5.90 |
| 52 Week High | $60.00 | $28.25 |
Technical Indicators
Market Signals| Indicator | ANGX | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.94 |
| Support Level | N/A | $9.15 |
| Resistance Level | N/A | $9.70 |
| Average True Range (ATR) | 0.00 | 0.51 |
| MACD | 0.00 | 0.49 |
| Stochastic Oscillator | 0.00 | 84.75 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc. Class A Common Stock
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.